ArticleNature communications2026
Brain and neural cell type proteomics reveal extracellular matrix proteins enriched in progressive multiple sclerosis.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Real-time sensing-integrated organoid-on-a-chip platforms: Technological progress and emerging biomedical applications.Bioactive materials · 2026Review
- Integrative Multi-Omics Analysis of Multiple Sclerosis Reveals Cell-Type-Specific Regulatory Landscapes and Discordant Methylation-Expression Coupling.International journal of molecular sciences · 2026Article
- Integrated proteogenomic profiling reveals coordinated differential expression signatures during neuroinflammation.Acta neuropathologica communications · 2026Article
- Microglia and neuroinflammation: function, heterogeneity, and crosstalk.Cellular & molecular immunology · 2026Review
- An Extracellular Matrix Aging Clock Based on Circulating Matrisome Proteins Predicts Biological Aging and Disease.Aging cell · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Progressive multiple sclerosis (PMS) is an autoimmune demyelinating disease of the central nervous system (CNS) in humans. PMS is defined by neuroinflammation and axonal damage with advancing neurological disabilities, although the underlying molecular mechanisms remain uncertain. To gain insight into the proteomic aspects of PMS, we used mass spectrometry to investigate proteomic profiles and specific protein changes in matched CNS tissues (white matter, cortex, and lesions) from persons with PMS and age/sex-matched other disease controls (ODCs). These studies were examined further using proteomes of primary human neural cell types (e.g., neurons, astrocytes, microglia, oligodendrocyte progenitor cells/OPCs) and CNS tissues from PMS mouse models. Extracellular matrix (ECM) related proteins, including the annexin, S100, and AHNAK protein families, were significantly enriched in PMS white matter, especially within demyelinated lesions compared to ODC tissues. These enriched proteins showed increased abundance in astrocytes, microglia, and OPCs compared to neurons. Annexin, S100, and AHNAK family proteins were also increased in the CNS of the cuprizone and experimental autoimmune encephalitis mouse models. These findings highlight the importance of ECM protein induction in CNS glial cells during PMS while providing potential therapeutic targets for future investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.